Government-Use License and Stem Cell-Based Pharmaceuticals Patent: Equitable Access to Covid-19 Medications

  • R. RAHMAH University of Airlangga, Surabaya, Indonesia

Abstract

ABSTRACT

 

In response to the outbreak of the Covid-19 pandemic, some pharmaceutical companies have patented their drugs to combat it, including those based on stem cells. Questions about how to access such drugs will likely be raised because patent protection grants an exclusive right to the patent owner, to prevent someone else from benefiting from a large-scale price increase. The document will then review the regulation and practice of government use in Indonesia and the possibility of such a mechanism to access Covid-19 drugs.

RESUMEN

 

En respuesta al brote de la pandemia Covid-19, algunas compañías farmacéuticas han patentado sus medicamentos para combatirlo, incluidos aquellos basados en células madre. Probablemente se plantearán preguntas sobre cómo acceder a dichos medicamentos porque la protección de la patente otorga un derecho exclusivo al titular de la misma, para evitar que otra persona pueda beneficiarse con un aumento de precio a gran escala. Luego, el documento revisará la regulación y la práctica del uso gubernamental en Indonesia y la posibilidad de dicho mecanismo para acceder a los medicamentos Covid-19.

Author Biography

R. RAHMAH, University of Airlangga, Surabaya, Indonesia
works as full-time Associate Professor in the Department of Private Law, Faculty of Law University of Airlangga, Surabaya, Indonesia. Mas Rahmah obtained her Doctor of Law from Universitas Airlangga, Master of Law from Monash University, Melbourne, Australia, and Bachelor of Law from University of Airlangga. She is the chief of Intellectual Property Centre of  Univesitas Airlangga  and Vice Chief of Indonesian Intellectual Property Lecturers Association.

References

ABRAR, P (2020). “Indian biotech firm stempeutics research gets us process patent for its novel stem cell drug. The Economic Time. March 4.”

AHK INDONESIEN. (2020). “Covid-19 development in Indonesia. April 30”.

BAKER B (2012). “Indonesian Compulsory Licenses Show Values of Pro-Access TRIPS-Flexibility Terms in Voluntary Licenses. InfoJustice.” Oct 30. http://infojustice.org/archives/27620.

BAKER, D (2004). “Financing drug research: what are the issues?. Ctr. For Econ”. Res. Sept 22 https://www.cepr.net/documents/publications/intellectual_property_2004_09.htm

BBC NEWS (2020). “Coronavirus declared global health emergency by WHO”. January 31. https://www.bbc.com/news/world-51318246

BEYER, P (2012). “Socially responsible licensing policies in the medical sector”. WTO Worshop on IP & public health. pp. 9-12.

BIOSCIENCE INSTITUTE (2020). “Covid-19, Stem cells among most promising treatments”. April 16. https://bioinst.com/en/covid-19-stem-cells-among-most-promising-treatments/

COHEN, RA, KIRZINGER, WK & GINDI, RM (2013). “Strategies used by adults to reduce their prescription drug costs”. NCHS Data Brief, 119, pp. 25-37.

DOHA DECLARATION (2001). “Doha Wto Ministerial 2001: Declaration on the TRIPS agreement and public health”. WT/MIN(01)/DEC/2, 20 November.

DRUG DISCOVERY (2020). “Citius, Novellus collaborate on novel stem-cell therapy for ARDS associated with Covid-19”. April 2, https://pharmaceutical-business-review.com/news/citius-novellus-covid-19/

GOLCHIN, A, SEYEDJAFARI, E & ARDESHIRYLAJIMI, A (2020). “Mesenchymal stem cell therapy for covid-19: present or future”. Stem Cell Rev Rep. 13, pp. 1–7.

HUSKAMP, HA, DEVERKA, PA, EPSTEIN, AM, EPSTEIN, RS, MCGUIGAN, KA & FRANK, RG (2003). “The effect of incentive-based formularies on prescription-drug utilization and spending”. NEw ENG. J. MED. 341, pp. 2224-2231.

LEE, RH, PULIN, AA, SEO, MJ, KOTA, DJ, YLOSTALO, J, LARSON, BL, ... & PROCKOP, DJ (2009). “Intravenous MSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell”. 5(1), pp. 54-63.

NORDRUM, A (2020). “Scientists use stem cells to treat Covid-19 patients in China, IEE spectrum”, 26 March 2020, https://spectrum.ieee.org/the-human-os/biomedical/devices/stem-cells-covid19-china

SAMI, T (2020). “Australia’s Mesoblast plans to evaluate its stem cell therapy in patients infected with Covid-19 Coronavirus-lungs-test-tube. Big World”. March 11,

SHETTY, AK (2020). “Mesenchymal stem cell infusion shows promise for combating coronavirus (Covid-19) Induced Pneumonia. Aging and Disease”. 11(2), pp. 462-464.

SHETTY, AK, UPADHYA, R, MADHU, LN, & KODALI, M (2019). “Novel insights on systemic and brain aging, stroke, amyotrophic lateral sclerosis, and alzheimer's disease”. Aging and Disease. 10, pp. 470-482.

THE JAKARTA POST (2020). “Indonesia's latest official COVID-19 figures”. May 29. https://www.thejakartapost.com/news/2020/03/23/indonesias-latest-covid-19-figures.html

THE NATIONAL LAW REVIEW (2020). “The global patent race for a Covid-19 vaccine”. April 22. https://www.natlawreview.com/article/global-patent-race-covid-19-vaccine

UNITED NATIONS ECONOMIC AND SOCIAL COUNCIL (2000). “The right to the highest attainable standard of health”. General Comment No 14. United Nations document E/C.12/2000/4. August 11. para. 43(d).

WHO. 2020. “Coronavirus disease (COVID-19) pandemic”.

WU, X, THI, VLD, HUANG, Y, BILLERBECK, E, SAHA, D, HOFFMANN, H H, ... & ANDRUS, L (2018). “Intrinsic immunity shapes viral resistance of stem cells”. Cell, 172(3), pp. 423-438.

Published
2020-09-18
How to Cite
RAHMAH, R. (2020). Government-Use License and Stem Cell-Based Pharmaceuticals Patent: Equitable Access to Covid-19 Medications. Utopía Y Praxis Latinoamericana, 25(1), 94-110. Retrieved from https://produccioncientificaluz.org/index.php/utopia/article/view/33675